RxDoctor Payments Data

Chia Hung Chen, MD

Ophthalmology · Wilmington, OHNPI 1871534420

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 93.0% of the total across 24 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Alcon accounts for 70.6% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2019 at $175 and has fallen 76.6% since, to $41 in 2025. That places this record below the midpoint for ophthalmology clinicians in OH, where the typical reported total is $1,115.

$552in general payments, 2019–2025

Across 24 payments — averaging $23.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$389
  • Aerie Pharmaceuticals, Inc.$40
  • Carl Zeiss Meditec AG$39
  • Apellis Pharmaceuticals, Inc.$29
  • Astellas Pharma US Inc$29
  • Genentech USA, Inc.$25
$248,617in research payments, 2019–2025

Across 2 payments — averaging $124,308 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Boehringer Ingelheim$249K

What the payments were for

  • Food & beverage$51393%
  • Gifts$397%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$552 in reported general payments places this provider in the 35th percentile of 640 ophthalmology providers in Ohio.

See all ophthalmology providers in Ohio

Medicare billing

Part B allowed, 2024
$256,144
Medicare patients
470
Services billed
2,895

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine20$14,019
RhopressaNetarsudil Mesylate30$11,880
Prednisolone Acetate284$9,263
MoxifloxacinMoxifloxacin Hcl262$7,656
Brimonidine Tartrate397$6,989
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat258$4,312
SimbrinzaBrinzolamide/Brimonidine Tart15$2,977
Latanoprost437$2,271
Travoprost12$2,164
Fluorometholone24$1,812
Acyclovir44$1,435
ErythromycinErythromycin Base42$918
Acetazolamide137$589
Difluprednate12$436
Timolol Maleate54$427

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Aerie Pharmaceuticals, Inc.Rhopressa$40$11,88030 claims
AlconSimbrinza$389$2,97715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 640 ophthalmology providers in Ohio.

Other ophthalmology in Wilmington

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →